Schering voluntarily recalls Ultravist(r)Injection 370 mgI/ml

Recall does not affect other Ultravist(r) concentrations
Root cause analysis is under way

Berlin, July 31, 2006 - Schering AG, Germany (FSE: SCH, NYSE: SHR) is
voluntarily recalling its X-ray contrast agent Ultravist(r) Injection 370
mgI/ml (iopromide injection) due to the potential that particulate matter
in conjunction with crystallization may be present in the product.
This recall does not include other concentrations of Ultravist (150 mgI/ml,
240 mgI/ml, 300mgI/ml). Production of Ultravist 370mgI/ml in China and
South Korea is not affected, and domestic supply in these two countries
will continue. In Japan, only Proscope(r) 370mgI/ml, in Spain, also
Clarograf(r) 370 mgI/ml is affected*.

Hospitals, imaging centers and other healthcare facilities should not use
any Ultravist(r) Injection 370 mgI/ml for patient care and should immediately
quarantine any product for return.

"Patient safety is our primary concern, and we are committed to taking
necessary steps in order to protect patients from any potential safety
risks," said Dr. Karin Dorrepaal, member of the Executive Board of Schering
AG, responsible for Diagnostic Imaging.

Schering is undertaking this recall of Ultravist 370 mgI/ml due to the
possible presence of particulate matter in conjunction with crystallization
in consideration of the potential for thromboembolic safety problems if the
product is administered to patients.
On Thursday, July 20, 2006, Berlex, Inc., the U.S. affiliate of Schering
AG, Germany, voluntarily recalled a single lot of Ultravist(r) Injection 370
mgI/ml, 125 ml lot number 41500A (NDC 50419-346-12, EXP 01/2007) in the
U.S. due to the presence of particulate matter in conjunction with
crystallization.

While Schering is investigating the situation it is taking precautionary
action and removing the concerned lots of this product. Berlex has informed
the FDA of its actions and maintains a close ongoing dialog with the
agency. Authorities in other countries have also been informed by Schering.
As is standard practice, all parenteral drug products should be inspected
visually for particulate matter and discoloration prior to administration,
and should not be used if particulates are observed or marked discoloration
has occurred.

*Proscope 370 mgI/ml is the trade name of Ultravist 370 mgI/ml in Japan,
Clarograf 370 mgI/ml is also the trade name of Ultravist 370 mgI/ml in
Spain.


Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic
Imaging as well as Specialized Therapeutics for disabling diseases. As a
global player with innovative products, Schering AG aims for leading
positions in specialized markets worldwide. With in-house R&D and supported
by an excellent global network of external partners, Schering AG is
securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve
the quality of life: making medicine work

This press release has been published by Corporate Communication of
Schering AG, Berlin, Germany.

Your contacts at Corporate Communication:
Media Relations: Oliver Renner, T: +49-30-468 124 31,
oliver.renner@schering.de
Media Relations: Verena von Bassewitz, T: +49-30-468 19 22 06,
verena.vonbassewitz@schering.de
Investor Relations: Dr Jost Reinhard, T: +49-30-468 150 62,
jost.reinhard@schering.de
Pharma Communication: Dr Claudia Schmitt, T: +49-30-468 158 05,
claudia.schmitt@schering.de

Your contact in the U.S.:
Media Relations: Kimberly Wix, T: +1-973-305 5258, kimberly_wix@berlex.com


Find additional information at: www.schering.de/eng